[White Paper] MadeFast™: A Single-Step CAR-T Manufacturing Platform with RapidCell™

Rethinking CAR-T Manufacturing: A Single-Step Path to Lower COGS and Higher Yield

Autologous CAR-T therapy has transformed outcomes for patients with hematologic malignancies. But its broader clinical impact remains constrained by the manufacturing process itself — a multi-step workflow that is complex, time-intensive, and costly enough to limit who can access these therapies.

The conventional approach requires three discrete interventions early in the process: T cell enrichment, activation, and lentiviral transduction. Each adds materials, labor, cleanroom occupancy, and variability. Published COGS models attribute more than half of per-dose cost to direct labor alone. For the field to scale, the architecture of manufacturing itself needs to change.

[Download the White Paper →]

A new framework: MadeFast™

MadeFast™ is Made Scientific's single-step manufacturing framework, designed to consolidate enrichment, activation, and transduction into a single operation early in the process. The platform is technology-agnostic by design — it defines a streamlined workflow architecture, while the specific vector technology used within it can be selected based on performance, availability, and program-specific needs.

In its first proof-of-concept study, Made Scientific evaluated Syenex's RapidCell™ Lentiviral Vector for T cells as the enabling technology for the consolidated step. The data were striking.

What the proof-of-concept showed

• Up to 97% CAR transduction in unfractionated PBMCs at MOI = 1 — achieved without any prior CD4/CD8 enrichment
• 30% greater viable CAR+ cell yield at MOI = 1 versus the conventional Control LVV condition, despite modestly lower fold expansion
• ≥97% viability across all conditions at harvest, with balanced CD4/CD8 ratios maintained throughout culture
• Superior in vitro cytotoxicity against Raji target cells at every effector-to-target ratio tested, with robust IFN-γ secretion confirming potent effector function

Why it matters

The advantage at MOI = 1 is directly relevant to cost. Lentiviral vector is typically one of the most expensive raw materials in CAR-T manufacturing, and consolidating activation and transduction into a single step further eliminates discrete reagents, reduces hands-on labor, and shortens the critical manufacturing path. Together, these efficiencies open a credible path to meaningfully lower per-dose COGS — without compromising product quality or functional potency.

MadeFast™ is early, but the first data are promising. The platform points toward a near-term future in which autologous CAR-T therapy can be manufactured faster, more reliably, and at a cost that expands rather than limits patient access.

Read the full white paper

The complete proof-of-concept dataset, experimental conditions, and discussion of next-stage development are available in MadeFast™: A Single-Step CAR-T Manufacturing Platform with RapidCell™. [Download the White Paper →]